يحاول ذهب - حر
Is This A Flu, Cold, Allergy Or Sinusitis?
December 2017 - January 2018
|PRIME Magazine
Cold, flu, allergy, sinusitis can all involve the upper airway and cause diseases. The upper airway includes the nose, sinus, throat and larynx above the voice box. Many patients cannot differentiate if they are having a flu or cold; a nose allergy or sinusitis.
-
As patients may have been breathing poorly for years, many with significant nose block do not think their nose is blocked at all. Instead, many of my patients complain instead of snoring, no sense of smell, or bad breath. Chronic nose block can be from structural causes like deviated nose bone, large inferior turbinate nose tissues and nose allergy. These structural problems also causes a patient to be more prone to bad nose congestion and more frequent cold and flu - akin to a river that does not flow and prone to festering infections.
Cold symptoms are due to virus infections, and usually last 7 to 10 days. There is stuffy nose, sneezing and sore throat. Unlike the flu, cold symptoms are milder, lower grade fever, and the patient is less ill and still active.
Flu symptoms are more intense and may last for weeks. Though arising from virus infections, a secondary bacterial infection is more common. Runny nose overshadows the nose block, and cough and bronchitis may be significant. There may be high fever, bad headache, vomiting, diarrhoea and severe body aches. Complications like pneumonia is higher in the elderly, very young, pregnant or immunocompromised patients.
هذه القصة من طبعة December 2017 - January 2018 من PRIME Magazine.
اشترك في Magzter GOLD للوصول إلى آلاف القصص المتميزة المنسقة، وأكثر من 9000 مجلة وصحيفة.
هل أنت مشترك بالفعل؟ تسجيل الدخول
المزيد من القصص من PRIME Magazine
PRIME Singapore
Living Large
The Illusion of Space in Small Homes
9 mins
February - March 2026
PRIME Singapore
Fend Off the Flames
Fire Safety Knowledge That Can Save Lives
7 mins
February - March 2026
PRIME Singapore
The World in Numbers
How Data Analytics Shapes Modern Decision-Making
14 mins
February - March 2026
PRIME Singapore
Thunder Struck
Chris Hemsworth: From God of Thunder to Hollywood Deity
29 mins
February - March 2026
PRIME Singapore
Ingesting Inflammation
Why Everyone is Talking About Anti-Inflammatory Diets
12 mins
February - March 2026
PRIME Singapore
Inked Later
Why More People Are Getting Tattoos After 40
7 mins
February - March 2026
PRIME Singapore
STUDY CONFIRMS ONE MONTH OF NO ALCOHOL MAKES REAL DIFFERENCE TO HEALTH
In 2013, Alcohol Change UK started the “Dry January” campaign, where people could commit to abstaining from drinking alcohol for the entire month.
2 mins
February - March 2026
PRIME Singapore
CERTAIN CHANGES IN DRIVING PATTERNS MAY POINT TO COGNITIVE DECLINE, DEMENTIA
Individuals with cognitive impairment are at a two-to five-fold increased risk of being involved in motor accidents, highlighting the deterioration of driving skills with a decline in cognitive function. A recent study published in Neurology suggests that changes in daily driving patterns recorded using a vehicle datalogger could reliably distinguish individuals with mild cognitive impairment (MCI) from those with normal cognition. The study’s findings suggest that data collected by vehicle data loggers could potentially be used in the early identification of individuals at risk of a motor crash or those with cognitive impairment, prior to in-person cognitive assessments or brain imaging scans. Driving data patterns could also serve as a tool to assess the effectiveness of interventions for treating cognitive impairment.
2 mins
February - March 2026
PRIME Singapore
LIFT ME UP
Volformer: The Rejuvenation Protocol Combining Precision Ultrasound and Volumetric RF
4 mins
February - March 2026
PRIME Singapore
TARGETING IDO1 FOR CANCER: NOVEL DEGRADERS SHOW PROMISE IN PRECLINICAL STUDIES
Cancer cells employ a variety of strategies to evade the immune system, and modern immunotherapies aim precisely at these escape mechanisms. However, such therapies are not always successful. A research team from the Max Planck Institute for Molecular Physiology in Dortmund and the AITHYRA Institute in Vienna has now developed a new class of compounds that specifically target and destroy the enzyme IDO1 – a key molecular switch that tumours use to suppress immune responses. They were also able to show that iDegs (IDO1 degraders) inhibit tumour growth in mice with SKOV-3 tumours, thereby prolonging survival time. This approach could markedly enhance the efficacy of existing immunotherapies and open new avenues in the fight against cancer. The new research was published in the journal Nature.
3 mins
February - March 2026
Translate
Change font size

